Buradasınız

Anasayfa » Content

Rosiglitazonun Metformin Kullanan Tip 2 Diabetes Mellitus'lu Hastalarda Serum Homosistein Ve Leptin Düzeylerine Etkileri

Effects of Rosiglitazon on Homocysteine and Leptin Levels in Patients with Type 2 Diabetes Mellitus Using Metformin

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Ojective: The prevalence of diabetes mellitus, a chronic progressive disease, is rising seriously. Rosiglitasone from the thiazolidinedion group is an oral antidiabetic extensively used in the treatment of type 2 DM. In this study we aimed to examine the effects of Rosiglitasone treatment on homocysteine and leptin levels. Material and method: The study included 20 voluntary patients (15 female and 5 male; mean age 51±12 years; and mean body mass index 28±5 kg/m2) who were diagnosed as type 2 DM and used Metformin, but whose blood glucose could not be regulated (high fasting blood glucose (FBG), postprandial blood glucose (PBG) and HbA1c). 4 mg/day Rosiglitasone was added to Metformin (2 x 850 mg -3 x 850 mg), which was used for treatment. FBG, PBG, HbA1c, serum lipid levels, homocysteine and leptin levels of the cases were determined before and at the end of 12-week treatment period. Results: At the end of 12-week treatment, FBG fell from 176±68 to 147±39 mg/dl (p<0.05), PBG from 224±56 to 182±46 mg/dl (p<0.05), and HbA1c from 8.7±2% to 7.6±1% (p<0.05), all the decreases being statistically significant. T. Chol., TG, LDL, VLDL and HDL levels increased, but the increase was not statistically significant. Hcy level fell from mean 10.3±2.6 to 5.14±2.7 |imol/L (p<0.05), while leptin level rose from mean 10.8±7 to 15.38±8 ng/ml (p<0.05). No changes were observed in total protein, albumin, AST and ALT levels. Conclusion: Rosiglitasone treatment brought about significant changes in Hcy and leptin levels, besides regulating the blood sugar. ©2004, Fırat Üniversitesi, Tıp Fakültesi
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Kronik ilerleyici bir hastalık olan Diabetes Mellitus'un prevalansı ciddi anlamda artmaktadır. Thiazolidinedion grubunda yer alan Rosiglitazon tip 2 DM'un tedavisinde yaygın olarak kullanılan oral antidiyabetiktir. Bu çalışmada Rosiglitazon tedavisinin homosistein ve leptin düzeyine etkilerini incelemeyi amaçladık. Gereç ve Yöntem: Tip 2 DM tanılı ve metformin kullanan ancak kan şekeri regülasyonu sağlanamayan (Açlık Kan Şekeri (AKŞ), Tokluk Kan Şekeri (TKŞ) ve HbAlc yüksek) 20 gönüllü hasta ( 5 erkek, 15 kadın, ortalama yaş 51±12 yıl ve ortalama vücut kitle indeksi 28±5 Kg/m2 olan) çalışmaya alındı. Hastaların tedavide kullandıkları metformine (2 X 850 mg - 3 X 850 mgr) 4 mg/gün roziglitazon ilave edildi. Olgularda tedavi öncesi ve 12 haftalık tedavi sonrası; AKŞ, TKŞ, HbAlc, serum lipit, homosistein ve leptin düzeyleri bakıldı. Bulgular: 12 haftalık tedavi sonrası; AKŞ 176±68 mg/dl'den, 147±39 mg/dl'ye (P<0,05), TKŞ 'i 224±56 mg/dl'den 182±46 mg/dl'ye (P<0,05), HbAlc %8.7±2 'den %7.6±1'e geriledi (p<0,05) ve istatistiksel olarak anlam taşımaktaydı. T. Kol, TG, LDL, VLDL ve HDL düzeyleri istatistiksel olarak anlamlı olmamak üzere arttı. Hcy düzeyi ortalama 10,3±2,6 |imol/L'den 5,14±2,7 |imol/L'ye geriledi (p<0,05). Leptin düzeyi ortalama 10,8±7 ng/ml'den 15,38±8 ng/ml'ye yükseldi (p<0,05). Total protein, albümin, AST ve ALT düzeyinde herhangi bir değişiklik gözlenmedi. Sonuç: Rosiglitazon tedavisi sonrasında kan şekeri regülasyonuna ilaveten homosistein ve leptin düzeylerinde anlamlı değişiklikler gözlenmiştir. ©2004, Fırat Üniversitesi, Tıp Fakültesi
FULL TEXT (PDF): 
PDF icon arastirmax-rosiglitazonun-metformin-kullanan-tip-2-diabetes-mellituslu-hastalarda-serum-homosistein-leptin-duzeylerine-etkileri.pdf
  • 3
86-90
  • Turkish

REFERENCES

References: 

1. Songer TJ, Zimmet PZ. Epidemiology of type II diabetes: an international perspective. Pharmacoeconomics 1995;8:1-11.
2. Chaour M, Theroux P, Gilfix BM. True fasting serum insulin resistance syndrome and coronary heart disease. Coron. Artery
Dis 1997; 8:683-688.
3. Laakso M. insulin resistance and coronary heart disease. Curr
Opin Lipidol 1996; 7: 217-226.
4. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805¬1837.
5. Fonseca VA, Foyt HL, Whitcomb R. Longterm effects of troglitasone: open-label extension studies in type 2 diabetes
patients. Diabetes Care 2000 23: 354-359.
6. Suter SL, Nolan JJ, Wallece P, Gumbiner B, Olefsky JM.
Metabolic effect of new oral hypoglyceamic agent cs -045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
7. Maggs DG, Buchanan TA, Burant CF. Metabolic effects of troglitasone monotherapy in type 2 diabetes mellitus a randomised, double- blind, placebo-controlled trial. Ann Intern
Med 1998;128: 176-185.
8. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW, The Troglitasone Study Group. Troglitasone monotherapy improves glycaemic contral in patients whit type 2 diabetes mellitus: a randomised, controlled study. J Clin Endocrinol Metab 1998; 83: 3169-3176.
9. Sanchez-Margalet V, Valle M, Ruz FJ, Gascon F, Mateo J, Goberna R. Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. J Nutr Biochem 2002; 13: 75¬79.
10. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects.
Atherosclerosis 1998; 139: 197-198.
11. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J Mol
Endocrinol 2001; 27: 85-91.
12. Lynn EG, Chung YH, Siow YL, Man RY, Choy PC.
Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. Biochim Biophys Acta, 1998; 1393:
317-324.
13. Hoogeveen EK, Kostense PJ, Beks PJ et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin dependent diabetes mellitus: a population-based study. Arterioscler Thromb
Vasc Biol 1998;18:133-138.14. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects.
Metabolism 1998; 47: 686-689.
15. Agata J, Masuda A, Takada M et al. High plasma immunoreactive leptin level in essential hypertension. Am J
Hypertens 1997; 10: 1171-1174.
16. Considine RV, Sinha MK, Heiman ML. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N
Engl J Med 1996; 334: 292-295.
17. Asakawa H, Tokunaga K, Kawakami F. Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus patients. J Diabetes Complications 2001; 15:
57-62.
18. King H, Aubert RF, Herman WH. Global burden of diabetes, 1995-20025; prevalence numerical estimates and projections.
Diabetes Care 1998; 21: 1414-1431.
19. Maruyama S, Yanagisawa K, Kanamuro R, Teno S, Iwamoto Y. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus. Diabetes
Res Clin Pract 2001; 53: 161-164.
20. Viberti GC. Rosiglitazone: potential beneficial impact on
cardiovascular disease. Int J Clin Pract 2003; 57: 128-134.
21. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes
mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151-163.
22. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI.
Rosiglitazone monotherapy is effective in patients with type 2
diabetes. Clin Endocrinol Metab 2001; 86: 280-288.
23. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitecomb
RW. The Troglitasone Study Group. Troglitasone in combination with sulfonylurea restores glycaemic control in patients with type
2 diabetes. Diabetes Care 1998; 21: 1462-1469.
24. Audelin MC, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001; 159: 497-511.
25. Boushey CJ, Beresford SA, Omen GS, Motulsky AG. A
quantative assesment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid
intakes. JAMA 1995; 274: 1049-1057.
26. Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J
Intern Med 1997; 242: 389-394.
27. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Total plasma homocysteine and insulin levels in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care 1999; 22: 2097¬2099.
89
Fırat Tıp
Dergis
i 2004;9(3): 86-90
28. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk
factors. Clin Ther, 2003; 25: 472-484.
29. Pelleymounter MA, Cullen MJ, Baker MB et al. Effects of the
obese gene product on body weight regulation in ob/ob mice.
Science 1995; 269: 540-543.
30. Imagawa K, Numata Y, Katsuura G, et al. Structure-Function Studies of Human Leptin. J Biol Chem 1998; 273: 35245-35249.
31. Fox C, Esparza J, Nicolson M et al. Plasma leptin concentrations in Pima Indians living in drastically different environments.
Diabetes Care 1999; 22: 413-417.
32. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188.
33. Moriya M, Okumura T, Takahashi N, Yamagata K, Motomura W, Kohgo Y. An inverse correlation between serum leptin levels
Özkan
v
e Ark.
and hemoglobin A1c in patients with non-insulin dependent
diabetes mellitus. Diabetes Res Clin Pract 1999; 43: 187-191.
34. Nolan JJ, Olefsky JM, Nyce MR, Considine RV, Caro JF. Effect
of troglitazone on leptin production. Studies in vitro and in
human subjects. Diabetes 1996; 45: 1276-1278.
35. Zhang B, Graziano MP, Doebber TW et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J
Biol Chem 1996; 271: 9455-9459.
36. Halle M, Berg A, Garwers U, Grathwohl D, Knisel W, Keul J. Concurrent reductions of serum leptin and lipids during weight loss in obese men with type II diabetes. Am J Physiol 1999;
277(2 Pt 1): E277-282.
37. Williams KV, Mullen M, Lang W, Considine RV, Wing RR.
Weight loss and leptin changes in individuals with type 2
diabetes. Obes Res 1999; 7: 155-163.

Thank you for copying data from http://www.arastirmax.com